Cancer News and Research

Latest Cancer News and Research

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

BioSante Pharmaceuticals, Inc. commented today that the recommendation on June 18, 2010 by the FDA Advisory Committee regarding the safety and efficacy of flibanserin (Boehringer-Ingelheim) will have no impact on its own ongoing development program or approval pathway for LibiGel (testosterone gel), for the treatment of hypoactive sexual desire disorder (HSDD).

22 Jun 2010

KYPHON ActivOs 10 Bone Cement with HA launched to treat patients with VCFs

Medtronic, Inc. today announced the launch of KYPHON ActivOs 10 Bone Cement with Hydroxyapatite, a polymethylmethacrylate bone cement containing hydroxyapatite for use in the treatment of patients with vertebral compression fractures who are undergoing minimally invasive surgery with KYPHON Balloon Kyphoplasty.

22 Jun 2010

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

OXiGENE, Inc., a clinical-stage, biopharmaceutical company developing novel therapeutics to treat cancer and eye diseases, announced today that the company presented an update on its ZYBRESTAT ophthalmology program, including encouraging preclinical data showing that the company's topical formulation achieved target retina/choroid concentrations with minimal systemic exposure.

22 Jun 2010

FDA grants approval for newest version of OnGuard Chest X-ray CAD technology

Riverain Medical announced today that the U.S. Food and Drug Administration has granted approval for the newest version of the OnGuard Chest X-ray Computer-Aided Detection technology. OnGuard identifies solitary pulmonary nodules that may represent early-stage lung cancer on an existing chest X-ray. This improved performance demonstrates a 73% reduction in false positive marks and 50% higher relative sensitivity compared to the original product.

22 Jun 2010

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Pfizer Inc. today announced the voluntary withdrawal from the U.S. market of the drug Mylotarg (gemtuzumab ozogamicin) for patients with acute myeloid leukemia (AML), a bone marrow cancer. The company took the action at the request of the U.S. Food and Drug Administration after results from a recent clinical trial raised new concerns about the product's safety and the drug failed to demonstrate clinical benefit to patients enrolled in trials.

22 Jun 2010

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Semafore Pharmaceuticals today announced the presentation of preliminary clinical data demonstrating that SF1126 has clinical activity in chronic lymphocytic leukemia (CLL). SF1126 is a novel peptidic prodrug that converts to LY294002, one of the most widely studied small molecule inhibitors of both phosphatidylinositol 3-kinase (PI3K) and mammalian target of rapamycin (mTOR). The results were presented at Cambridge Healthtech Institute's 8th Annual Next-Gen Kinase Inhibitors Oncology & Beyond Conference being held June 21-23, 2010, in Cambridge, Massachusetts.

22 Jun 2010

Cernostics, Geisinger announce personalized healthcare collaboration

Cernostics Inc., a biotechnology firm specializing in advanced cancer diagnostics, and Geisinger Health System, a $2.1 billion integrated health services organization, today announced a partnership in personalized healthcare. They will focus on developing diagnostic technologies to detect subtle differences in the cellular and molecular makeup of patient tissue samples. These technologies promise to more effectively predict disease progression and identify patients who are most likely to be receptive to specific cancer treatments.

22 Jun 2010

Celator announces expansion of research agreement with Cephalon

Celator Pharmaceuticals today announced that it has expanded its research agreement with Cephalon, Inc.. The research agreement provides for the utilization of Celator's proprietary technology in an ongoing drug development and life-cycle management program at Cephalon.

22 Jun 2010

ASIR technique reduces already low radiation dose delivered during CTC by another 50%: Study

A newly adapted low-dose computed tomography technique called adaptive statistical iterative reconstruction can help radiologists reduce the already low radiation dose delivered during CT colonography by another 50 percent, according to a study published in the July issue of the American Journal of Roentgenology.

22 Jun 2010

Patel had the patient’s best interests in mind: Defense says

The manslaughter trial against the Bundaberg based surgeon Dr. Jayant Patel that has been going on for 13 weeks now, is in its final phases now. In Dr. Patel’s defense barrister, Michael Byrne QC completed his final address to the jury in the Queensland Supreme Court.

21 Jun 2010

Malpractice reformers get grants, but fear of lawsuits remains ER scourge

A New York judge's unusual technique — listening to the families of injured people, knowing something about medicine — for dealing with difficult medical malpractice cases will be among 20 explored with $3 million grants as part of the health overhaul, The Associated Press reports. The judge, Douglas McKeon, said, "I don't discuss settlement offers with families right away. … I just say, 'Tell me a little bit about your loved one.'"

21 Jun 2010

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

One of the leading cancer centers in the Middle East has become among the first in the region to introduce fast and efficient RapidArc® radiotherapy treatments from Varian Medical Systems. Al Amal Hospital in Doha, Qatar, has treated nine brain cancer, prostate cancer and head & neck cancer patients with RapidArc since commencing treatments in early May, and it now plans to roll out the technology for many more indications.

21 Jun 2010

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante Pharmaceuticals, Inc., today announced that the independent Data Monitoring Committee (DMC) of the ongoing LibiGel® Cardiovascular (CV) and Breast Cancer Safety Study unanimously recommended study continuation without modifications, after its third review of the study's unblinded safety data. The review was based on data from almost 1,500 women-years of exposure.

21 Jun 2010

BioSante announces $15 million registered direct offering

BioSante Pharmaceuticals, Inc. today announced that it has received commitments from several institutional investors to purchase $15 million of securities in a registered direct offering. The investors are Deerfield Management Company and other institutional investors. BioSante expects to receive net proceeds of approximately $14.2 million after deducting placement agent fees and other offering expenses.

21 Jun 2010

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Dako, a Danish-based world leader in tissue-based cancer diagnostics, and Omnyx, a leader in digital pathology solutions, announced today that they have entered into a three-year agreement to develop clinical algorithms for digital pathology. The aim is to support pathologists in generating even more accurate, objective and reproducible diagnostic results.

21 Jun 2010

Families of children with cancer are visiting Capitol Hill to seek more federal funding for cancer research

Today and tomorrow hundreds of families of children with cancer are visiting Capitol Hill to ask Congress one question: Where is the research money that was authorized by the Caroline Pryce Walker Conquer Childhood Cancer Act of 2008?

21 Jun 2010

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Immunomedics Inc. today announced that clinical trial results from the Phase IIb EMBLEM study of epratuzumab, a monoclonal antibody targeting CD22, in patients with moderate-severe systemic lupus erythematosus were presented at the 2010 annual Congress of the European League Against Rheumatism in Rome, Italy.

21 Jun 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

GTx, Inc. announced that Ostarine (GTx-024, formerly MK-2866) increased lean body mass and leg press strength in a head to head study evaluating Ostarine and another selective androgen receptor modulator, MK-3984, in postmenopausal women. The data were presented yesterday at the 2010 Annual Meeting of the Endocrine Society. GTx is developing its lead SARM, Ostarine, for the treatment of cancer induced muscle wasting (cancer cachexia).

21 Jun 2010

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

Aeterna Zentaris Inc., a late-stage drug development company specialized in oncology and endocrine therapy, today announced that a poster on its oral synthetic growth hormone secretagogue/ghrelin receptor agonist, AEZS-130, was presented yesterday at the 92nd Annual Endocrine Society (ENDO) Meeting and Expo, which is held through June 22, 2010 at the San Diego Convention Center in San Diego, California.

21 Jun 2010

PHCG recognized with CEO Cancer Gold Standard accreditation in fight against cancer

Publicis Healthcare Communications Group, the world's largest healthcare communications group, has received CEO Cancer Gold Standard accreditation, recognizing the organization's commitment to reducing the risk of cancer for employees and their families by promoting healthy lifestyle choices, encouraging early detection through cancer screenings, and ensuring access to quality treatment.

21 Jun 2010

Cancer News and Research

Latest Cancer News and Research

FDA Advisory Committee recommendation against flibanserin will not affect LibiGel program: BioSante

KYPHON ActivOs 10 Bone Cement with HA launched to treat patients with VCFs

OXiGENE reports encouraging data from ZYBRESTAT program at Glaucoma and Retinopathies 2010 conference

FDA grants approval for newest version of OnGuard Chest X-ray CAD technology

Pfizer announces voluntary withdrawal of Mylotarg from U.S. market following FDA request

Semafore's SF1126 peptidic prodrug demonstrates clinical activity in chronic lymphocytic leukemia

Cernostics, Geisinger announce personalized healthcare collaboration

Celator announces expansion of research agreement with Cephalon

ASIR technique reduces already low radiation dose delivered during CTC by another 50%: Study

Patel had the patient’s best interests in mind: Defense says

Malpractice reformers get grants, but fear of lawsuits remains ER scourge

Al Amal Hospital in Qatar commences treatment with Varian's RapidArc radiotherapy

Independent DMC recommends continuation of BioSante's ongoing LibiGel CV and Breast Cancer Safety Study

BioSante announces $15 million registered direct offering

Dako, Omnyx partner to develop clinical algorithms for digital pathology

Families of children with cancer are visiting Capitol Hill to seek more federal funding for cancer research

Phase IIb EMBLEM study results of epratuzumab in patients with SLE presented at EULAR 2010

Ostarine increases muscle mass and strength in postmenopausal women: Study

Positive preclinical data on Aeterna Zentaris' AEZS-130/Ghrelin Receptor Agonist presented at ENDO meeting

PHCG recognized with CEO Cancer Gold Standard accreditation in fight against cancer

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Cancer News and Research

Latest Cancer News and Research

Industry Focus eBook: Oncology eBook

Scaling organ‑chip technology for human‑relevant drug discovery

Unlocking drug amorphization: Continuous, solvent-free twin screw granulation

How can super-resolution technology help study neurotransmission?

Newsletters you may be interested in